Lifecycle Management of Generic product in US market
In the US Market, lifecycle management for generic products includes developing and implementing plans to maximize an item’s market potential from launch to decline. It starts with market research and approval of regulatory involving submission of an Abbreviated New Drug Application (ANDA) to demons...
Gespeichert in:
Veröffentlicht in: | International Journal of Drug Regulatory Affairs 2024-09, Vol.12 (3), p.47-54 |
---|---|
Hauptverfasser: | , , , , |
Format: | Artikel |
Sprache: | eng |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | In the US Market, lifecycle management for generic products includes developing and implementing plans to maximize an item’s market potential from launch to decline. It starts with market research and approval of regulatory involving submission of an Abbreviated New Drug Application (ANDA) to demonstrate bioequivalence to the branded product followed by comprehensive market analysis to identify opportunities and assess rivals. Companies use aggressive pricing and marketing techniques to swiftly increase their market share after a product is approved. Continuous monitoring and adaptability to changes in the market, updates to regulations, and competitive actions are crucial throughout the lifecycle. This review focuses on Market entry strategy, Product launch, Market landscape of Generic Drugs in US. |
---|---|
ISSN: | 2321-7162 2321-6794 |
DOI: | 10.22270/ijdra.v12i3.693 |